Dificid

Dificid is a brand name of fidaxomicin, approved by the FDA in the following formulation(s):

DIFICID (fidaxomicin - tablet; oral)

• 
  Manufacturer: OPTIMER PHARMS
  
  Approval date: May 27, 2011
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Dificid been approved?

No. There is currently no therapeutically equivalent version of Dificid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dificid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Polymorphic crystalline forms of tiacumicin B
  Patent 7,378,508
  Issued: May 27, 2008
  Inventor(s): Chiu; Yu-Hung & Che; Tessie Mary & Romero; Alex & Ichikawa; Yoshi & Shue; Youe-Kong
  Assignee(s): Optimer Pharmaceuticals, Inc.
  The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
  
  Patent expiration dates:
  
  
  • July 31, 2027
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
  Patent 7,863,249
  Issued: January 4, 2011
  Inventor(s): Chiu; Yu-Hung & Che; Tessie Mary & Romero; Alex & Ichikawa; Yoshi & Shue; Youe-Kong
  Assignee(s): Optimer Pharmaceuticals, Inc.
  The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
  
  Patent expiration dates:
  
  
  • July 31, 2027
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  18-membered macrocycles and analogs thereof
  Patent 7,906,489
  Issued: March 15, 2011
  Inventor(s): Shue; Youe-Kong & Hwang; Chan-Kou & Chiu; Yu-Hung & Romero; Alex & Babakhani; Farah & Sears; Pamela & Okumu; Franklin
  Assignee(s): Optimer Pharmaceuticals, Inc.
  The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
  
  Patent expiration dates:
  
  
  • March 4, 2027
    
    ✓ 
    Patent use: TREATMENT OF MICROBIAL INFECTIONS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 27, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Dificid Consumer Information (Drugs.com)
• Dificid Consumer Information (Wolters Kluwer)
• Dificid Consumer Information (Cerner Multum)
• Dificid Advanced Consumer Information (Micromedex)
• Fidaxomicin Consumer Information (Wolters Kluwer)
• Fidaxomicin Consumer Information (Cerner Multum)
• Fidaxomicin Advanced Consumer Information (Micromedex)